BACKGROUND: There is limited evidence for the use of enhanced recovery after surgery (ERAS) in patients undergoing hepatectomy, and the impact of the evolution of ERAS over time has not been examined. This study sought to evaluate the effect of an evolving ERAS program in patients undergoing hepatectomy for colorectal liver metastases (CRLM). METHODS: A multimodal ERAS program was introduced in 2/2008. Consecutive patients undergoing hepatectomy for CRLM between 2/2008 and 9/2012 were included in the study. Data were collected prospectively. Retrospective analysis compared an early ERAS cohort (2/2008-4/2010) with a later cohort with a matured ERAS program (5/2010-8/2012). RESULTS: Length of stay reduced as experience of ERAS increased (Log-rank χ(2) = 10.43, P = 0.001). Although median length of stay remained unchanged (6 days), the probability of hospitalization beyond 10 days was 25% in the early cohort compared with 7% in the later cohort. Critical care utilization reduced over time (75.5% vs. 54.7%, P < 0.0001). Complications occurred in 38.2%, with no difference in between cohorts. One postoperative death occurred in the early cohort (<0.3%). CONCLUSIONS: This study suggests that as experience of ERAS evolves, there is a progressive reduction in hospitalization and critical care admission. This is without any increase in morbidity and mortality.
BACKGROUND: There is limited evidence for the use of enhanced recovery after surgery (ERAS) in patients undergoing hepatectomy, and the impact of the evolution of ERAS over time has not been examined. This study sought to evaluate the effect of an evolving ERAS program in patients undergoing hepatectomy for colorectal liver metastases (CRLM). METHODS: A multimodal ERAS program was introduced in 2/2008. Consecutive patients undergoing hepatectomy for CRLM between 2/2008 and 9/2012 were included in the study. Data were collected prospectively. Retrospective analysis compared an early ERAS cohort (2/2008-4/2010) with a later cohort with a matured ERAS program (5/2010-8/2012). RESULTS: Length of stay reduced as experience of ERAS increased (Log-rank χ(2) = 10.43, P = 0.001). Although median length of stay remained unchanged (6 days), the probability of hospitalization beyond 10 days was 25% in the early cohort compared with 7% in the later cohort. Critical care utilization reduced over time (75.5% vs. 54.7%, P < 0.0001). Complications occurred in 38.2%, with no difference in between cohorts. One postoperative death occurred in the early cohort (<0.3%). CONCLUSIONS: This study suggests that as experience of ERAS evolves, there is a progressive reduction in hospitalization and critical care admission. This is without any increase in morbidity and mortality.
Authors: Lucas W Thornblade; Yongwoo D Seo; Tracy Kwan; Jane H Cardoso; Eric Pan; Gregory Dembo; Raymond S W Yeung; James O Park Journal: J Gastrointest Surg Date: 2018-02-05 Impact factor: 3.452
Authors: Nicolai A Schultz; Peter N Larsen; B Klarskov; L M Plum; Hans-Jørgen Frederiksen; Henrik Kehlet; Jens G Hillingsø Journal: World J Surg Date: 2018-06 Impact factor: 3.352
Authors: Andrew J Page; Aslam Ejaz; Gaya Spolverato; Tiffany Zavadsky; Michael C Grant; Daniel J Galante; Elizabeth C Wick; Matthew Weiss; Martin A Makary; Christopher L Wu; Timothy M Pawlik Journal: J Gastrointest Surg Date: 2014-12-04 Impact factor: 3.452
Authors: Bobby V M Dasari; Rasha Rahman; Shakeeb Khan; Davinia Bennett; James Hodson; John Isaac; Ravi Marudanayagam; Darius F Mirza; Paolo Muiesan; Keith J Roberts; Robert P Sutcliffe Journal: HPB (Oxford) Date: 2015-06-23 Impact factor: 3.647
Authors: Emad Ali Ahmed; Roberto Montalti; Daniele Nicolini; Paolo Vincenzi; Martina Coletta; Andrea Vecchi; Federico Mocchegiani; Marco Vivarelli Journal: Medicine (Baltimore) Date: 2016-07 Impact factor: 1.889